98593-59-0Relevant academic research and scientific papers
METHODS OF TREATING FRAGILE X SYNDROME, DOWN?S SYNDROME, AUTISM AND RELATED DISORDERS
-
, (2012/02/01)
Disclosed herein are methods of treating fragile X syndrome, fragile X-associated tremor/ataxia syndrome, Down?s syndrome and other forms of mental retardation, and/or autism comprising administering a GABA B agonist prodlug to a subject suffering therefrom. The GABAB agonist prodrugs can be compounds of Formula (I), (II) or (III) as disclosed herein
Use of GABA and GABAB agonists
-
, (2008/06/13)
The present invention provides methods of stimulating tissue growth, including islet cell growth, by administering GABA or a GABA agonist to act on GABAB receptors and GABAB-like receptors to activate cell replication.
3-thienyl- and 3-furylaminobutyric acids. Synthesis and binding GABA(B) receptor studies
Berthelot,Vaccher,Flouquet,Debaert,Luyckx,Brunet
, p. 2557 - 2560 (2007/10/02)
Baclofen (β-(p-chlorophenyl)-GABA) is a selective agonist for the bicuculline-insensitive GABA(B) receptor. The search for new compounds that bind to the GABA(B) receptor is very important to clarify structural requirements. We report herein the synthesis and the binding studies of variously substituted 3-thienyl- and 3-furylaminobutyric acids. 4-Amino-3-(5-methyl-2-thienyl)butyric acid (5d) and 4-amino-3-(5-chloro-2-thienyl)butyric acid (5h) are potent and specific ligands for GABA(B) receptor. The IC50 values for the displacement of (R)-(-)-[3H]baclofen are 1.34 and 0.61 μM for 5d and 5h, respectively, as compared to 0.33 μM for baclofen.
